A REVIEW ON ANTIASTHMATIC DRUGS

Pharmacy

Asthma is a chronic respiratory condition that affects millions of people worldwide, characterized by inflammation and narrowing of the airways, resulting in recurrent episodes of wheezing, coughing, chest tightness, and shortness of breath. Despite the availability of numerous medications, a significant number of asthma patients still experience symptoms that are inadequately controlled, highlighting the need for new treatments. A new drug, Dupilumab, recently has been approved for the treatment of asthma. Dupilumab is a monoclonal antibody that targets the interleukin-4 receptor alpha (IL-4Ra), which is involved in the inflammatory response in asthma. It has been shown to reduce asthma exacerbations and improve lung function in patients with moderate-to-severe asthma.Clinical trials has shown that Dupilumab, used in combination with other asthma medications, significantly reduces the frequency of exacerbations, improves lung function, and reduces symptoms in patients with moderate-to-severe asthma. Additionally, it has also been shown to improve quality of life and reduce the need for oral corticosteroids. Despite its potential benefits, Thus, careful patient selection and monitoring the drug.The pathogenic process begins with the inhalation of an allergen or an irritant, such as cold air, which causes bronchial hypersensitivity and, as a result, causes the airways to become inflamed and produce more mucus As a result, there is a notable rise in airway resistance, which is most noticeable during expiration. Benralizumab is a type of biologic medication that was approved by the U.S. Food and Drug Administration for the treatment of severe asthma. It is designed to target a specific type of white blood cell called eosinophils, which are involved in the inflammatory response in asthma. Dupilumab is a monoclonal antibody medication that was approved for the treatment of moderate to severe asthma. It works by blocking two proteins involved in the inflammatory response in asthma: interleukin-4 (IL-4) and interleukin-13 (IL-13). Tezepelumab is a monoclonal antibody medication that was approved for the treatment of severe asthma. It works by blocking a protein called thymic stromal lymphopoietin (TSLP), which is involved in the allergic response in asthma. Bronchial thermoplasty is a non-medication treatment for severe asthma that was approved by the . It involves the use of a catheter inserted through the nose or mouth to deliver controlled heat energy to the airway walls, reducing the amount of muscle tissue and decreasing airway responsiveness these all medications helps to treat asthma.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.